Characterizing modifier genes of cardiac fibrosis phenotype in hypertrophic cardiomyopathy. (1st May 2021)

• Record Type: Journal Article
• Authors: Xu, Fuyi; Chen, Yuanjian; Tillman, Kaitlin A.; Cui, Yan; Williams, Robert W.; Bhattacharya, Syamal K.; Lu, Lu; Sun, Yao
• Is Part Of: International journal of cardiology. Volume 330(2021)
• Page Start: 135
• Page End: 141
• Publication Date: 2021-05-01
• Subjects: Hypertrophic cardiomyopathy -- Modifier genes -- Cardiac fibrosis -- Murine genetic reference population; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2021.01.047
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: Clinical phenotypes of hypertrophic cardiomyopathy (HCM) vary greatly even among patients with the same gene mutations. This variability is largely regulated by unidentified modifier loci. The purpose of the study is to identify modifier genes for cardiac fibrosis—a major phenotype of HCM—using the BXD family, a murine cohort. Methods: The relative severity of cardiac fibrosis was estimated by quantitation of cardiac collagen volume fraction (CCVF) across 66 members of the BXD family. Quantitative trait locus (QTL) mapping for cardiac fibrosis was done using GeneNetwork. Candidate modifier loci and genes associated with fibrosis were prioritized based on an explicit scoring system. Networks of correlation between fibrosis and cardiac transcriptomes were evaluated to generate causal models of disease susceptibility. Results: CCVF levels varied greatly within this family. Interval mapping identified a significant CCVF-related QTL on chromosome (Chr) 2 in males, and a significant QTL on Chr 4 Mb in females. The scoring system highlighted two strong candidate genes in the Chr 2 locus— Nek6 and Nr6a1 . Both genes are highly expressed in the heart. Cardiac Nek6 mRNA levels are significantly correlated with CCVF. Nipsnap3b and Fktn are lead candidate genes for the Chr 4 locus, and both are also highly expressed in heart. Cardiac Nipsnap3b gene expression correlates well with CCVF. Conclusion: Our study demonstrated that candidate modifier genes of cardiac fibrosis phenotype in HCM are different in males and females. Nek6 and Nr6a1 are strong candidates in males, while Nipsnap3b and Fktn are top candidates in females. Highlights: The study aims to identify modifier genes that regulate severity of fibrosis in HCM. BXD family, a murine GRPs expresses different levels of cardiac fibrosis. Interval mapping characterizes significant fibrosis-related QTLs. Candidate modifier genes within these QTLs are identified.